Vitae Pharmaceuticals (VTAE) Misses Q3 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Vitae Pharmaceuticals (VTAE) Ends 3Q With Cash Available Through 2016; Piper Jaffray Raises Price Target to $18
November 6, 2015 11:26 AM ESTPiper Jaffray reiterated an Overweight rating on Vitae Pharmaceuticals (NASDAQ: VTAE), and raised the price target to $18.00 (from $16.00), following the company's 3Q earnings report. Vitae ended 3Q:15 with $69 million, sufficient to fund the company through 2016. Lead candidate VTP-43742, inhibiting the RORt/IL-17 pathway, is currently in a multiple ascending dose trial in both healthy... More
